TrialJournal of gastroenterology2026
A phase I/II clinical trial of neoadjuvant docetaxel/oxaliplatin/S‑1 (DOS) combination therapy for gastroesophageal junction adenocarcinoma.
Koshi Kumagai et al.PubMed ↗Publisher ↗
No numbers read from the abstract.